[HLA DR7 as a protective factor against gold salt toxicity in rheumatoid arthritis].
We performed a study of antigens HLA type I and II (specificity DR) in 90 patients with diagnosis of Rheumatoid Arthritis (RA) treated with Sodium Aurothiomalate (SATM) in order to detect the presence of an antigen HLA which could act as a protective factor against toxicity by SATM. Our results demonstrated a decrease in the frequency of the antigen DR7 in patients with toxicity by SATM, which suggests a protective factor of this antigen against the development of toxic reactions due to gold salts.
Rodríguez Pérez
M
M
Servicio de Reumatología, Hospital Clínico Universitario, Granada.
González Domínguez
J
J
Matarán Pérez
L
L
Salvatierra Ríos
D
D
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006052:Gold Sodium Thiomalate / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D015809:HLA-DR7 Antigen / Q000032:analysis / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged
D015809:HLA-DR7 Antigen; D006052:Gold Sodium Thiomalate
HLA DR7 como factor de protección frente a la toxicidad por sales de oro en la artritis reumatoide.